A clinically approved oral vaccine against pneumotropic bacteria induces the terminal maturation of CD83+ immunostimulatory dendritic cells.
Dendritic cells (DCs) are important antigen-presenting cells of the immune system that have attracted interest as cellular adjuvants to induce immunity in clinical settings. We have investigated the effects of Broncho-Vaxom, an oral vaccine composed of lysates from eight pneumotropic bacteria, on human monocyte-derived dendritic cells (moDCs). Broncho-Vaxom induced the terminal maturation of CD83+ moDCs. MoDCs stimulated with Broncho-Vaxom displayed a phenotype of activated DCs with high levels of major histocompatibility complex (MHC) molecules and increased levels of adhesion and co-stimulatory molecules. In addition, moDCs activated with Broncho-Vaxom exhibited enhanced T cell-stimulatory capacity in the allogeneic mixed leukocyte reaction. Broncho-Vaxom at 100 microg/ml was as potent as TNF-alpha at 1000 U/ml in activating human moDCs. Neither LPS-like activity nor bacterial DNA was found to be responsible for the maturation-inducing activity of Broncho-Vaxom, suggesting that Broncho-Vaxom contains other bacterial factors that are capable of inducing the terminal maturation of moDCs. In DC-based immunotherapy, Broncho-Vaxom could be used as a stimulus of DC maturation, which meets the standards of good manufacturing practice (GMP). In addition, vaccination with Broncho-Vaxom-loaded moDCs may be an attractive treatment option in preventing recurrent airway infection in predisposed individuals.
Department of Urology, Anichstrasse 35, University of Innsbruck, A-6020, Innsbruck, Austria. claudia.rieser@uibk.ac.at
C
C
Zelle-Rieser
R
R
Ramoner
G
G
Bartsch
M
M
Thurnher
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000284:Administration, Oral; D015703:Antigens, CD; D001419:Bacteria; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D002454:Cell Differentiation / Q000276:immunology; D002457:Cell Extracts; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D016130:Immunophenotyping; D007369:Interferon Inducers / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000276:immunology*; D009000:Monocytes / Q000166:cytology / Q000276:immunology; D018410:Pneumonia, Bacterial / Q000276:immunology* / Q000517:prevention & control; D013601:T-Lymphocytes / Q000276:immunology; D000097802:CD83 Antigen; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D001428:Bacterial Vaccines; D002457:Cell Extracts; D007136:Immunoglobulins; D007369:Interferon Inducers; D008562:Membrane Glycoproteins; D000097802:CD83 Antigen; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates